DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and ...
March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...
The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...
Increased antibiotic use can lead, seemingly paradoxically, to more problematic infections, as the bacteria evolve to resist ...
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
The US Food and Drug Administration (FDA) has broadened the approval of Furoscix® (furosemide injection) to treat edema in ...
Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...
Increased antibiotic use can lead, seemingly paradoxically, to more problematic infections, as the bacteria evolve to resist the treatment. The answer to this antimicrobial resistance, which the ...
A drug already used to treat people who have diabetes and/or chronic kidney disease could have added heart disease benefits, ...
10d
Most of ProKidney's money went toward R&D as it attempts to get its first-in-class cellular therapy for Chronic Kidney ...
Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback